GSK Stock Dives After Judge Allows Zantac Cancer Lawsuits To Go Forward
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2153417526-fc6ade053d5b43638e1d603f627e4b42.jpg)
Vivian Wan / Bloomberg via Getty Images' title='Signage for GSK Plc displayed at the company's headquarters in the Brentford suburb of London, UK, on April 30, 2024'>
Vivian Wan / Bloomberg via Getty Images
Key TakeawaysGSK Plc American depositary receipts (ADRs) sank in intraday trading Monday after a Delaware judge allowed lawsuits to continue claiming the pharmaceutical firm's former heartburn medicine, Zantac, causes cancer.The company denies the accusations, and vows an immediate appeal.GSK said the ruling was inconsistent with one by a federal court in 2022.
American depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a Delaware court ruled that lawsuits claiming the drugmaker’s discontinued heartburn treatment, Zantac, causes cancer can go forward.According to multiple reports, Superior Court judge Vivian Medinilla ruled late last week that the some 75,000 plaintiffs weren’t relying on bad science in their arguments. She noted that experts have reached different conclusions, and that a jury should be the one to determine the merits of a technical debate among opposing scientists. GSK Disagrees With Ruling, Vows Immediate AppealGSK announced that it will immediately seek an appeal of the ruling. It said that “there is no consistent or reliable evidence” that Zantac increases the risk of any cancer. It added that the Delaware ruling “contradicts the Federal Court’s (Multidistrict Litigation) ruling under the same legal standard, which dismissed all cases alleging five cancer types, in December 2022.”Along with GSK, Zantac has been owned by several companies over the years, including Pfizer (PFE) and Sanofi (SNY), which now holds the U.S. rights. However, four years ago, the Food and Drug Administration (FDA) asked pharmaceutical companies to remove all products with ranitidine, the active ingredient in Zantac, from the U.S. market.GSK noted that despite the court decision, its capital allocation priorities remained unchanged, and it will have no impact on the firm’s investment plans for growth.ADRs of GSK tumbled 9.3% to $40.63 as of 11:45 a.m. ET Monday but remain up about 10% for the year. Sanofi ADRs were little changed, but Pfizer shares were about 2% higher. Read the original article on Investopedia.
Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!
Account Frozen
Your account is frozen. You can still view content but cannot interact with it.
Please go to your settings to update your account status.
Open Profile Settings